Clinical trials: Mild to Moderate Alzheimer's Disease
Mild to Moderate Alzheimer's Disease
Study of LM11A-31-BHS in Mild-moderate AD Patients
The purpose of this study is to determine the safety of 2 doses of LM11A-31-BHS in 180 patients with Alzheimer's Disease versus placebo and to access biomarker and clinical exploratory endpoints of LM11A-31-BHS
- Trial name
- NCT03069014
- Testing
- 400mg LM11A-31-BHS, 800mg LM11A-31-BHS
- Where
- 21 sites in Austria, Czechia and 3 more
- Volunteers
- 242 people
- Sponsor
- PharmatrophiX Inc.
Alzheimer Disease
18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00103649
- Testing
- xaliproden (SR57746A)
- Where
- 121 sites in United States, Canada
- Volunteers
- 1,306 people
- Sponsor
- Sanofi
Dementia, Alzheimer Type
Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease
A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease.
- Trial name
- NCT00154635
- Testing
- DCB-AD1
- Where
- 2 sites in Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Alzheimer Disease
Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease
The primary purpose of the study is to assess whether SAM-531, an investigational drug, is safe and well tolerated, compared with placebo (a medically inactive substance), in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00481520
- Testing
- SAM-531
- Where
- 7 sites in United States
- Volunteers
- 72 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer's Disease
Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine
The purpose of this study is to evaluate and compare the changes of cognitive function (as measured by ADAS-Cog) in the two group of patients with Alzheimer's disease (AD) associated with and without white matter changes after…
- Trial name
- CAREER (NCT01380288)
- Testing
- rivastigmine patch
- Where
- 16 sites in South Korea
- Volunteers
- 300 people
- Sponsor
- Dong-A University
Alzheimer's Disease
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
This is a long term extension study to evaluate safety and tolerability of subjects who complete study M11-793 which is evaluating a new treatment for subjects with mild to moderate Alzheimer's disease on stable doses of…
- Trial name
- NCT01690195
- Testing
- ABT-126
- Where
- 39 sites in United States, Canada and 5 more
- Volunteers
- 343 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Alzheimer's Disease, Blood Brain Barrier
Pilot Clinical Trial to Assess the Safety of NMS-01 in Patients With Mild to Moderate Alzheimer's Disease
A single-center, single-arm, prospective, open-label, pilot clinical trial to evaluate the safety and efficacy of the Focused ultrasound stimulator system (NMS-01) for transient Blood-Brain Barrier (BBB) opening in patients with…
- Trial name
- NMSBBBOYUSH01 (NCT07869238)
- Testing
- NMS-01
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Neumous Inc.
Alzheimer's Dementia
Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)
This study is a randomized, double-blind, placebo-controlled phase 3 design aimed at further verifying the safety and efficacy of Wujia Yizhi granules for mild-to-moderate Alzheimer's dementia
- Trial name
- NCT06534723
- Testing
- Wujia Yizhi granules
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Sichuan Jishengtang Pharmaceutical Co., Ltd.
Alzheimer Disease
Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
ALZN002-01 is a first-in-human, randomized, double-blind, placebo-controlled, parallel-group, phase 1/2a study of autologous amyloid beta mutant peptide-pulsed dendritic cells (ALZN002) in subjects with mild-to-moderate dementia…
- Trial name
- NCT05834296
- Testing
- ALZN002 (autologous DCs pulsed with E22W mutant peptide).
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alzamend Neuro, Inc.
Alzheimer's Disease
Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)
The main purpose of this study was to assess the safety and efficacy of MK-1942 as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD) dementia.
- Trial name
- NCT05602727
- Testing
- MK-1942
- Where
- 74 sites in United States, Argentina and 9 more
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
A Pilot Study of tDCS for Mild to Moderate Alzhemier's Disease
The primary objective of this preliminary study is to investigate whether the transcranial direct current stimulation (tDCS) improves the cognitive function in patients with Alzheimer's disease
- Trial name
- NCT02227953
- Testing
- Yband (YDT-201N)
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Samsung Medical Center
Alzheimer's Disease, Dementia
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or…
- Trial name
- NCT01969123
- Testing
- Drug: EVP-6124
- Where
- 82 sites in United States, Australia and 10 more
- Volunteers
- 474 people
- Sponsor
- FORUM Pharmaceuticals Inc
Alzheimer's Disease
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's Disease.
- Trial name
- NCT01689246
- Testing
- TRx0237 150 mg/day, TRx0237 250 mg/day
- Where
- 121 sites in United States, Australia and 14 more
- Volunteers
- 891 people
- Sponsor
- TauRx Therapeutics Ltd
Alzheimer Disease
Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type
The objective of this trial was to assess the dose-response relationship of symptomatic efficacy of talsaclidine base on ADAScog and to assess safety and tolerability
- Trial name
- NCT02249403
- Testing
- Talsaclidine 6 mg, Talsaclidine 12 mg, Talsaclidine 24 mg
- Volunteers
- 362 people
- Sponsor
- Boehringer Ingelheim
Alzheimer's Disease
Resveratrol for Alzheimer's Disease
Resveratrol is derived from plants and is found in highest levels in red wine and the skin of red grapes. A recent study reported that monthly and weekly consumption of red wine is associated with a lower risk of dementia.
- Trial name
- NCT01504854
- Testing
- Resveratrol
- Where
- 26 sites in United States
- Volunteers
- 119 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Alzheimer Disease
Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects
This is an investigator-initiated clinical (IIT)study.The main purpose of this study was to evaluate the diagnostic efficacy of XTR006 PET qualitative reading and quantitative analysis in detecting mild cognitive…
- Trial name
- NCT06151808
- Testing
- XTR006
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Alzheimer Disease
Alzheimer's Disease Acitretin Medication
The trials investigates the changes of cerebral spinal fluid (CSF) soluble alpha-secretase cleaved APP (APPsα) levels under oral therapy with acitretin 30mg daily in patients with mild to moderate Alzheimer's disease (AD).The…
- Trial name
- ADAM (NCT01078168)
- Testing
- Acitretin
- Where
- 2 sites in Germany
- Volunteers
- 22 people
- Sponsor
- K. Lieb
Alzheimer's Disease, Central Nervous System Diseases
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
This study is being conducted to determine the safety and effect on cognitive function of the investigational medication, EVP-6124, in individuals with mild to moderate probable Alzheimer's disease.
- Conditions
- Alzheimer's Disease, Central Nervous System Diseases, Cognition
- Trial name
- NCT01073228
- Testing
- EVP-6124
- Where
- 54 sites in United States, Romania and 3 more
- Volunteers
- 409 people
- Sponsor
- FORUM Pharmaceuticals Inc
Alzheimer's Disease
The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease
This is a national multicenter, double-blind, randomized, parallel-group trial of 12 months in duration. Following a 4 week wash-out period, subjects will be randomized to one of 2 treatment groups: (1) galantamine CR 24 mg/day…
- Trial name
- AD-Combi (NCT01921972)
- Testing
- Galantamine CR, Memantine
- Volunteers
- 232 people
- Sponsor
- Charite University, Berlin, Germany
Alzheimer Disease
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-2214 in adults with mild cognitive impairment or mild-to-moderate Alzheimer's Disease.
- Trial name
- NCT05466422
- Testing
- MK-2214
- Where
- 12 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC